Precision medicine in type 2 diabetes
Year: 2019
Type: dissertation
Abstract: Type 2 diabetes is a progressive disease characterised by raised blood glucose levels. Lowering of blood glucose is required to prevent symptoms of diabetes and to reduce the risk of people with type 2 diabetes developing diabetes-related complications. Metformin is the initial drug of choice to lower blood glucose for most people. However, for many people metformin eventually fails to control blood glucose and additional medication is required. At least four different types of glucose-lowering medication are recommended after metformin in current type 2 diabetes treatment guidelines. Choosing the best medication is left to the clinician and patient and is a major clinical dilemma. The degree of glucose-lowering appears to vary greatly between people for all the medication options. The same medication may appear to have a marked effect in one patient but little effect in another. Similarly, only some people develop side-effects. Despite this apparent variation it is largely unknown whether differences in treatment response and risk of side-effects can be predicted based on an individual patient’s characteristics. The aim of this thesis is to establish whether simple patient characteristics are associated with differences in treatment effect for common glucose-lowering medications. If they are, this could inform a precision medicine approach in type 2 diabetes, where medications are targeted to those people most likely to benefit.
Source: Figshare
Author: John Dennis
Institution: University of Exeter
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Alexander von Humboldt-Stiftung, Wellcome Trust, European Federation of Pharmaceutical Industries and Associations, University Hospitals Plymouth NHS Trust, National Institute for Health and Care Research, University of Oxford, European Commission, North Bristol NHS Trust, Medical Research Council, NIHR Exeter Clinical Research Facility
Awards: MICA: MRC APBI STratification and Extreme Response Mechanism IN Diabetes - MASTERMIND, New insights from Neonatal Diabetes., Urinary C-peptide creatinine ratio and glycaemic response to incretin based treatments in type 2 diabetes, G3207356259, G393177772, G5702163051, G6382720711, Stratified medicine in Type 2 diabetes: Insights from the study of drug response., European Medical Information Framework, Integrating clinical features and biomarkers to improve diabetes classification and treatment in young adults
OpenAlex ID: W2978275126
